Stock TERN TERNS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Terns Pharmaceuticals, Inc.

Equities

TERN

US8808811074

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 24/06/2024 BST 		5-day change 1st Jan Change
7.52 USD +4.01% Intraday chart for Terns Pharmaceuticals, Inc. -5.53% +15.87%
06-22 Terns Pharmaceuticals, Inc. Presents New Preclinical Data Supporting TERN-501 in Combination with A GLP-1R Agonist for Obesity CI
05-13 Terns Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Business Summary

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

Number of employees: 66

Managers

Managers TitleAgeSince
Amy Burroughs CEO
 Chief Executive Officer 54 02-06
Mark Vignola DFI
 Director of Finance/CFO 47 10/08/20
Bryan Yoon COO
 Chief Operating Officer 46 31/10/20
Jeffrey R. Jasper CTO
 Chief Tech/Sci/R&D Officer - 05/01/22
Justin Ng IRC
 Investor Relations Contact - -
Emil T. Kuriakose PRN
 Corporate Officer/Principal 44 30/04/23
Melita Jung PRN
 Corporate Officer/Principal 47 04-21

Members of the board

Members of the board TitleAgeSince
David Fellows CHM
 Chairman 67 30/11/20
Jeffrey Kindler BRD
 Director/Board Member 68 30/11/20
Carl Gordon BRD
 Director/Board Member 59 30/09/18
Hong Bo Lu BRD
 Director/Board Member 53 31/03/20
Radhika Tripuraneni BRD
 Director/Board Member 44 25/07/22
Jill Quigley BRD
 Director/Board Member 49 30/11/20
Amy Burroughs CEO
 Chief Executive Officer 54 02-06
Ann Taylor BRD
 Director/Board Member 67 27/09/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 64,677,145 63,520,830 ( 98.21 %) 0 98.21 %

Shareholders

NameEquities%Valuation
OrbiMed Advisors Private Equity
11.78 %
7,619,135 11.78 % 46 M $
Vivo Capital LLC
9.644 %
6,237,329 9.644 % 37 M $
Deep Track Capital LP
9.431 %
6,100,000 9.431 % 37 M $
Millennium Management LLC
5.308 %
3,432,792 5.308 % 21 M $
Venrock Associates
5.272 %
3,410,058 5.272 % 20 M $
Soleus Capital Management LP (Investment Management)
5.166 %
3,341,120 5.166 % 20 M $
BlackRock Advisors LLC
4.798 %
3,103,127 4.798 % 19 M $
Citadel Securities GP LLC
4.585 %
2,965,586 4.585 % 18 M $
LAV Management Co., Ltd.
4.486 %
2,901,566 4.486 % 17 M $
Fidelity Management & Research Co. LLC
4.271 %
2,762,126 4.271 % 17 M $

Company contact information

Terns Pharmaceuticals, Inc.

1065 East Hillsdale Boulevard Suite 100

94404, Foster City

+650 525 5535

http://www.ternspharma.com
address Terns Pharmaceuticals, Inc.(TERN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
7.52 USD
Average target price
14.21 USD
Spread / Average Target
+89.02%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TERNS PHARMACEUTICALS, INC. Stock Terns Pharmaceuticals, Inc.
+15.87% 486M
MODERNA, INC. Stock Moderna, Inc.
+37.76% 52.5B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-7.47% 39.01B
LONZA GROUP AG Stock Lonza Group AG
+36.73% 39.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.93% 26.2B
CELLTRION, INC. Stock Celltrion, Inc.
-11.17% 26.57B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+16.45% 28.2B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+45.05% 14.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+33.13% 12.62B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-3.46% 11.74B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TERN Stock
  4. Company Terns Pharmaceuticals, Inc.